A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo- and active-controlled study to
assess the efficacy and safety of CD-008-0045 in patients with generalized anxiety disorder
(GAD). Each patient will participate in the study for the period of approximately 37 weeks:
Screening and Run-in period: 1 week; Study Treatment period: 32 weeks; Follow-up period: 4
weeks.